Physician profile
Chelsea Hendrix
NPI 1104341247
$5,985.37
in general payments reported to CMS, 2019-2025
25 companies · $1,417 in 2025
The $1,417 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $536 · 2022: $1,340 · 2023: $1,400 · 2024: $1,292 · 2025: $1,417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,110.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,951.82 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $692.27 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $477.12 | 2021-2025 | Stelara, Tremfya, Simponi |
| Genzyme Corporation | $243.77 | 2024-2025 | |
| Gilead Sciences, INC. | $166.24 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $128.61 | 2022-2024 | Dupixent |
| Ardelyx, INC. | $126.04 | 2022-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $124.80 | 2021-2024 | Dificid |
| Celgene Corporation | $119.54 | 2021-2024 | Zeposia |
| Merit Medical Systems INC | $112.02 | 2025 | Esophyx |
| Ironwood Pharmaceuticals, INC | $110.98 | 2022-2024 | Linzess |
| Pfizer INC. | $101.34 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $93.42 | 2021-2024 | Entyvio |
| Phathom Pharmaceuticals, INC. | $90.40 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $67.87 | 2024-2025 | Rebyota, Clenpiq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $62.25 | 2022-2025 | Sucraid |
| Redhill Biopharma INC. | $58.65 | 2021-2023 | Talicia, Aemcolo, Movantik |
| Endogastric Solutions, INC | $55.62 | 2024 | Esophyx |
| Madrigal Pharmaceuticals | $52.89 | 2024-2025 | Rezdiffra, Resmetirom |
| Enterra Medical, INC. | $40.19 | 2025 | |
| Boston Scientific Corporation | $37.31 | 2021-2023 | |
| Nestle Healthcare Nutrition INC. | $30.05 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $18.78 | 2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $11.88 | 2021 | |
| Vbi Vaccine (Delaware) INC. | $11.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chelsea Hendrix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.